VetMedGuide

Vet Med Guide

Companion animal in a veterinary exam setting with medication reference materials.
Pharmaceuticals2026-06-26 · 19 min read

Numelvi vs Apoquel vs Zenrelia: Comparing Dog Allergy JAK Inhibitors

Compare the three oral dog-allergy JAK inhibitors — Numelvi, Apoquel, and Zenrelia — on FDA dosing, age and weight limits, vaccine warnings, and openFDA adverse-event counts.

Ran Chen
Ran Chen
Founder, VetMedGuide. Life-sciences operator and 10× global market-access lead.
Published

Oral Janus kinase (JAK) inhibitors have revolutionized the management of canine pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis. For more than a decade, oclacitinib (Apoquel) stood as the sole oral representative of this class in veterinary medicine. However, the therapeutic landscape has expanded rapidly. The FDA approval of ilunocitinib (Zenrelia) in September 2024 and the recent FDA approval of atinvicitinib (Numelvi) on February 25, 2026, have created a highly competitive three-way choice for veterinary clinicians and pet owners.

Choosing the right oral allergy medication requires understanding key pharmacological differences. While all three drugs target the signaling pathways that drive inflammation and itch, they differ substantially in their receptor selectivity, dosing schedules, age and weight restrictions, and safety warnings—particularly regarding vaccinations and immunosuppression.

This guide provides a comprehensive clinical comparison of Numelvi, Apoquel, and Zenrelia, backed by FDA product labels, freedom of information (FOI) summaries, and openFDA adverse event data.

The Core Comparison at a Glance

Before examining the clinical nuances of each molecule, the table below provides a direct comparison of the key regulatory, dosing, and safety parameters of the three FDA-approved canine JAK inhibitors.

Parameter Apoquel (Oclacitinib) Zenrelia (Ilunocitinib) Numelvi (Atinvicitinib)
Active Ingredient Oclacitinib maleate Ilunocitinib Atinvicitinib tablets
Manufacturer Zoetis Inc. Elanco US Inc. Merck Animal Health
FDA Approval Date 2013 September 2024 February 25, 2026
FDA Status NADA 141-345 NADA 141-585 NADA 141-596
Mechanism of Action JAK1/JAK3 inhibitor (some JAK2 activity) JAK1/JAK2/TYK2 inhibitor (JAK1-potent, non-selective) Second-generation, highly selective JAK1 inhibitor (≥10× over JAK2/JAK3/TYK2)
Approved Indications Control of pruritus associated with allergic dermatitis and control of atopic dermatitis Control of pruritus associated with allergic dermatitis and control of atopic dermatitis Control of pruritus associated with allergic dermatitis
Age Limit ≥ 12 months ≥ 12 months ≥ 6 months
Minimum Weight 6.6 lbs (3.0 kg) 6.6 lbs (3.0 kg) 4.4 lbs (2.0 kg)
Dosing Frequency 0.4–0.6 mg/kg twice daily for up to 14 days, then once daily 0.6–0.8 mg/kg once daily from Day 1 0.8–1.2 mg/kg once daily from Day 1, with food
Loading Phase? Yes (14 days twice daily) No (Once daily from start) No (Once daily from start)
Boxed Warning? No Yes (Vaccination & immunosuppression risks) No
Vaccine Interaction May administer inactivated vaccines; do not vaccine with MLV during loading phase Strictly prohibited concurrent vaccination (28-day wash-out before & after) Precautions apply; check label for vaccine timing
openFDA Event Count 29,296 reports 1,343 reports 0 reports (Approved 2026)

How the Mechanisms of Action Differ: JAK1 Selectivity

To understand why these medications exhibit different clinical profiles, it is necessary to examine how they interact with the Janus kinase enzyme family. Janus kinases (comprising JAK1, JAK2, JAK3, and TYK2) are intracellular enzymes that bind to cytokine receptors on cell membranes. When a cytokine (such as an interleukin) binds to its receptor, the associated JAK enzymes phosphorylate, initiating a signaling cascade via Signal Transducer and Activator of Transcription (STAT) proteins. This STAT pathway translocates to the cell nucleus, turning on genes that drive inflammation, itching, and immune responses.

Different cytokines rely on different pairings of JAK enzymes:

  • JAK1 is the primary driver of pruritic and pro-inflammatory cytokines, specifically Interleukin-31 (IL-31), which directly stimulates pruriceptive nerves, and IL-4, IL-6, IL-13, and IL-5, which mediate allergic responses.
  • JAK2 is essential for hematopoiesis (the production of red blood cells, white blood cells, and platelets) by mediating erythropoietin (EPO), thrombopoietin (TPO), and granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • JAK3 and TYK2 are critical for immune surveillance, helping regulate natural killer (NK) cells, T-lymphocytes, and interferon signaling.

Apoquel (Oclacitinib): First-Generation JAK Inhibition

Oclacitinib was designed to inhibit JAK1-dependent cytokines. However, as a first-generation inhibitor, its selectivity is relative. In cell-free biochemical assays, oclacitinib inhibits JAK1 and JAK3, and to a lesser extent, JAK2. When administered at the recommended doses, it effectively controls itching by blocking IL-31. However, because it also blocks JAK3 and shows cross-reactivity with JAK2, it carries a wider risk profile for mild to moderate suppression of hematopoiesis and immune surveillance, particularly during its twice-daily loading phase.

Zenrelia (Ilunocitinib): JAK1/JAK2/TYK2 Inhibition

The FDA's FOI summary for Zenrelia (NADA 141-585) describes ilunocitinib as a non-selective Janus kinase inhibitor with high potency for JAK1, JAK2, and TYK2. It blocks the pruritogenic and allergic cytokines that depend on JAK1, but — unlike Numelvi — it does not spare the JAK2-dependent hematopoietic pathways. This matters clinically: because JAK2 drives red blood cell, white blood cell, and platelet production, JAK2 inhibition is the pharmacological reason Zenrelia's openFDA profile (see below) shows measurable hematologic signals such as neutropenia, leukopenia, lymphopenia, and decreased hematocrit. Suppression of immune defense also remains a clinical reality, reflected in Zenrelia's boxed warning.

Numelvi (Atinvicitinib): Second-Generation Selectivity

Atinvicitinib represents a "second-generation" advancement in veterinary JAK inhibitors. Merck Animal Health designed the molecule to possess even tighter binding affinity for the JAK1 enzyme, resulting in a higher selectivity index relative to JAK2, JAK3, and TYK2.

The clinical benefit of this advanced selectivity is twofold:

  1. Reduced Hematological Off-Target Effects: Sparing the JAK2 pathway preserves normal red and white blood cell production under standard dosing.
  2. Sparing Developmental Pathways: Because it minimizes interference with non-target kinases, atinvicitinib does not interfere with the growth and skeletal development pathways of older puppies, allowing its approval in dogs as young as 6 months of age.

Age and Weight Restrictions: Sparing the Developing Canine

One of the most significant clinical distinctions among these three medications is the minimum age at which they can be safely administered.

The 12-Month Floor: Apoquel and Zenrelia

Both Apoquel and Zenrelia are strictly restricted to dogs 12 months of age and older.

This restriction is not a bureaucratic safety margin; it is based on severe adverse effects observed in target animal safety studies of younger dogs:

  • Apoquel in Young Puppies: When oclacitinib was administered to dogs younger than 6 months of age, safety trials were halted due to the development of bacterial pneumonia, demodicosis (mange), and severe lesions of the skin and lymph nodes. The drug's relative lack of selectivity suppressed the immature immune system, leaving the puppies unable to fight off opportunistic pathogens.
  • Zenrelia in Young Puppies: In target animal safety studies of ilunocitinib in young dogs, researchers observed bone marrow hypoplasia (suppression of blood cell production), lymph node depletion, and severe infestations of Demodex mites.

Because of these findings, the FDA labels for both oclacitinib and ilunocitinib carry explicit contraindications against use in dogs under one year of age.

The 6-Month Approval: Numelvi

In contrast, Numelvi is approved for dogs 6 months of age and older, provided they weigh at least 4.4 lbs (2 kg).

During its FDA approval process (NADA 141-596), Merck Animal Health presented safety data showing that atinvicitinib's refined selectivity profile did not induce the bone marrow or systemic immune suppression seen with older JAK inhibitors in growing dogs. For primary care veterinarians, this approval is highly valuable:

  • It provides an oral option for juvenile dogs (6–12 months old) suffering from early-onset atopic dermatitis.
  • Prior to Numelvi's approval, clinicians managing moderate-to-severe pruritus in dogs under one year of age were limited to monoclonal antibody injections (Cytopoint) or short courses of corticosteroids, as oral JAK inhibitors were locked behind the 12-month age restriction.

Dosing Regimens: The Loading Phase Challenge

Dosing schedules influence owner compliance and clinical outcomes. The three JAK inhibitors employ different strategies to achieve rapid itch relief while maintaining long-term safety.

Apoquel's Induction Period

Apoquel is dosed at 0.4 to 0.6 mg/kg administered orally twice daily (every 12 hours) for the first 14 days, followed by a transition to once daily (every 24 hours) for maintenance therapy.

  • The Rationale: Because oclacitinib has a short half-life and its JAK1 selectivity is moderate, the twice-daily loading phase is necessary to quickly downregulate the inflammatory and pruritic cytokines and provide immediate relief.
  • The Clinical Risk: The 14-day twice-daily period represents the window of highest drug exposure. Because oclacitinib targets JAK3 and JAK2 at higher concentrations, this loading phase is associated with transient drops in white blood cell counts and increased susceptibility to gastrointestinal upset. Additionally, transitioning the dog from twice-daily to once-daily maintenance can sometimes trigger a brief recurrence of itching (often referred to as the "Apoquel rebound"), requiring careful client communication.

Once-Daily Dosing: Zenrelia and Numelvi

Both Zenrelia and Numelvi eliminate the need for a twice-daily loading phase.

  • Zenrelia (Ilunocitinib): Administered at 0.6 to 0.8 mg/kg (0.27–0.36 mg/lb) once daily from Day 1, with or without food.
  • Numelvi (Atinvicitinib): Administered at 0.8 to 1.2 mg/kg (0.36–0.54 mg/lb) once daily from Day 1, given with food, using weight-banded scored tablets (4.8, 7.2, 21.6, and 31.6 mg).

This once-daily start is highly beneficial for owner compliance. Administering a pill once a day is easier for clients than managing a twice-daily schedule that must be tracked and changed after exactly two weeks. Furthermore, starting once-daily avoids the peak drug concentrations associated with Apoquel’s loading phase, promoting a more stable immunologic transition.

Safety Warnings and the Vaccination Dilemma

All oral JAK inhibitors carry precautions regarding immune system suppression. Because they block cytokine signaling, they can reduce the body's ability to defend against viral, bacterial, fungal, and parasitic infections, and they can mask the signs of systemic disease. However, the regulatory warnings and vaccine protocols differ significantly.

Zenrelia’s Boxed Warning and the Vaccine Wash-Out

Zenrelia carries a prominent Boxed Warning on its FDA-approved label. This boxed warning is a critical consideration for clinical practice.

[!IMPORTANT] Zenrelia Vaccine Wash-Out Protocol: Zenrelia must be discontinued for at least 28 days to 3 months prior to receiving any vaccine, and it must not be restarted until at least 28 days after the vaccination.

This means that if a dog on Zenrelia is due for their annual core vaccines (such as Rabies or DAPP), the clinician must stop the medication, leave the dog without oral allergy control for at least 28 days, administer the vaccine, and wait another 28 days before resuming therapy. This creates a 56-day gap in itch control, during which the dog's allergic dermatitis is highly likely to flare.

  • The History: When Zenrelia was first approved in 2024, the label carried a warning regarding the risk of fatal vaccine-induced disease, particularly associated with modified-live virus (MLV) vaccines. This warning stemmed from a laboratory safety study where unvaccinated puppies administered three times the labeled dose of Zenrelia and concurrently exposed to parvovirus and distemper experienced severe, fatal illness.
  • The September 2025 Update: Following the review of additional clinical field data, the FDA approved a label change in September 2025 that removed the warning regarding fatal vaccine-induced disease.
  • The Current Boxed Warning: The label retains a boxed warning regarding the risk of an inadequate immune response to vaccines. Because ilunocitinib suppresses the immune system's cytokine signaling, a dog vaccinated while taking Zenrelia may fail to produce protective antibody titers, rendering the vaccine ineffective.

Apoquel's Vaccine Protocol

Apoquel does not carry a boxed warning. Its vaccine guidelines are much more flexible:

  • The Apoquel label states that the drug has been safely co-administered with inactivated (killed) vaccines, such as rabies and leptospirosis.
  • It advises against administering modified-live vaccines (such as DAPP) during the 14-day twice-daily loading phase.
  • For dogs on long-term once-daily maintenance therapy, clinical experience and manufacturer data show that Apoquel does not prevent the development of a protective immune response to routine booster vaccinations.

Numelvi's Vaccine Guidelines

Numelvi, as a second-generation selective JAK1 inhibitor, does not carry a boxed warning. Because of its targeted selectivity, its interference with vaccine-induced antibody production is minimized. However, because it is an immunosuppressive drug, veterinarians are advised to check the product label for specific precautions regarding vaccine administration. As a best practice, clinicians should monitor titers or consider timing vaccinations during periods of low allergen exposure if a temporary drug holiday is feasible.

Data-Driven Insights: openFDA Adverse Event Profiles

To evaluate the real-world safety profiles of these medications, we queried the openFDA Animal Adverse Event Database (data snapshot current through June 2026).

While adverse event reports are voluntary and do not prove causality, they provide a valuable signal regarding the types and frequencies of clinical reactions encountered in veterinary practice.

Oclacitinib (Apoquel) reporting volume

  • Total Reports: 29,296

  • Species Breakdown: Dog: 27,691 reports; Cat: 398 reports (unlabeled use); Other species: 1,207 reports

  • Top 10 Clinical Reactions:

    1. Lack of efficacy - NOS: 3,590 reports
    2. Vomiting: 3,344 reports
    3. Ineffective atopy control: 2,705 reports
    4. Diarrhea: 2,261 reports
    5. Lethargy: 2,168 reports
    6. Ineffective, loss of effect: 1,807 reports
    7. Other abnormal test result (laboratory findings): 1,389 reports
    8. Elevated alanine aminotransferase (ALT): 1,134 reports
    9. Seizures: 1,111 reports
    10. Elevated alkaline phosphatase (ALP/SAP): 1,056 reports

  • Clinical Analysis: The high total number of reports reflects Apoquel's 13 years on the market and its status as one of the most widely prescribed drugs in veterinary history. The appearance of "Lack of efficacy" and "Ineffective, loss of effect" as top reports highlights the clinical reality of chronic atopic dermatitis, where dogs can experience flares due to secondary infections (such as Malassezia or Staphylococcus) or develop resistance over time. The presence of elevated liver enzymes (ALT and ALP) underscores the need for routine blood monitoring in dogs on long-term therapy. The seizure signal, while present, represents a tiny fraction of total users but warrants caution in dogs with pre-existing epilepsy.

Ilunocitinib (Zenrelia) reporting volume

  • Total Reports: 1,343

  • Species Breakdown: Dog: 1,312 reports; Cat: 1 report; Other: 30 reports

  • Top 10 Clinical Reactions:

    1. Lack of efficacy - NOS: 247 reports
    2. Lethargy: 183 reports
    3. Diarrhea: 154 reports
    4. Vomiting: 130 reports
    5. Neutropenia: 116 reports
    6. Leucopenia NOS: 114 reports
    7. Decreased hematocrit: 104 reports
    8. Elevated alkaline phosphatase (ALP): 91 reports
    9. Lymphopenia: 83 reports
    10. Elevated alanine aminotransferase (ALT): 74 reports

  • Clinical Analysis: Despite being on the market for a much shorter period than Apoquel, Zenrelia has accumulated a significant number of reports. Crucially, the hematological reactions—neutropenia (low neutrophils), leukopenia (low white blood cells), lymphopenia (low lymphocytes), and decreased hematocrit (anemia)—appear prominently within the top 10 reported adverse events. This provides real-world validation of target animal safety studies, indicating that ilunocitinib exhibits a measurable suppressive effect on bone marrow and immune cells.

Atinvicitinib (Numelvi) reporting volume

  • Total Reports: 0
  • Clinical Analysis: Because Numelvi was approved on February 25, 2026, it does not yet have a reporting footprint in the openFDA database. Post-marketing safety data will begin to accumulate as the drug enters widespread clinical use throughout 2026. Clinicians should monitor patients taking Numelvi with the same diligence applied to any newly launched therapeutic molecule.

Clinical Decision Framework

For veterinary professionals, choosing between these three options involves matching the patient's age, the owner's budget, vaccine requirements, and safety risk tolerances. The following decision rules reflect the label differences above:

  1. Start with the age gate. No oral JAK inhibitor is labeled for dogs under 6 months. For dogs 6 to 11 months old and at least 4.4 lb (2 kg), Numelvi is the only labeled oral option — Apoquel and Zenrelia are both contraindicated under 12 months.
  2. Check the vaccine calendar. If core or lifestyle vaccines are due within roughly the next 2–3 months, Zenrelia's 28-day-before to 28-day-after (56-day) vaccine window makes it a poor fit; Numelvi or Apoquel avoid that constraint.
  3. Weigh dosing convenience against history. For owners who want no twice-daily loading phase, Numelvi or Zenrelia (both once daily from Day 1) are simpler than Apoquel's 14-day twice-daily induction.
  4. Apply the hematologic filter. For dogs with a history of bone-marrow suppression or abnormal blood counts, expect closer CBC monitoring on Zenrelia (which inhibits JAK2 and shows neutropenia/leukopenia signals in openFDA), and consider a non-immunosuppressive alternative such as Cytopoint. Our deeper Apoquel (oclacitinib) side effects and FDA adverse-event analysis covers the oclacitinib safety signal in more detail.

For the single-drug monographs behind this comparison, see Numelvi for dogs, Apoquel for dogs, and our Zenrelia vs. Apoquel label comparison. For the wider allergic-itch landscape — including Cytopoint, steroids, and antihistamines — see our dog allergy medication overview.

When is Numelvi (Atinvicitinib) the Best Choice?

  • Juvenile Atopic Dogs (6 to 12 months): Numelvi is the only oral JAK inhibitor approved for this age group, filling a major clinical gap for young dogs where injectable monoclonal antibodies (Cytopoint) are either unavailable, cost-prohibitive, or clinically insufficient.
  • Active Vaccine Schedule: For dogs requiring active socialization (e.g., boarding, training class) that need frequent vaccine updates (Lyme, Influenza, Bordetella, DAPP), Numelvi avoids the strict 56-day vaccine wash-out required by Zenrelia.
  • Compliance-Minded Owners: It offers once-daily dosing from Day 1, avoiding the complexity of Apoquel's twice-daily 14-day induction period.
  • Small Dogs: Approved down to 4.4 lbs (2 kg), compared to the 6.6 lbs (3 kg) limit for Apoquel and Zenrelia.

When is Apoquel (Oclacitinib) the Best Choice?

  • Established Safety History: With over a decade of clinical use, Apoquel's long-term safety profile, rare side effects, and management protocols are thoroughly understood by the veterinary community.
  • Established Formulations: Apoquel is available in multiple tablet strengths sized to weight bands, which most dogs take readily.
  • Short-Term Flare Management: For dogs experiencing acute, seasonal allergy flares that require immediate, short-term relief, Apoquel's twice-daily loading phase can suppress itching very rapidly.

When is Zenrelia (Ilunocitinib) the Best Choice?

  • Cost-Effectiveness: Elanco has positioned Zenrelia as a more economical alternative to Apoquel in many markets. For owners of large-breed dogs requiring lifetime allergy management, the cost savings of Zenrelia can make long-term therapy financially sustainable.
  • Stable Patients with Completed Vaccines: In mature dogs (over 1 year of age) that have completed their primary vaccine series and are on a stable, triennial (every 3 years) booster schedule, the vaccine wash-out requirement is less frequent, making Zenrelia's once-daily convenience highly practical.

Patient Monitoring Protocol

Regardless of which JAK inhibitor is selected, all dogs receiving long-term therapy should undergo structured veterinary monitoring:

  1. Baseline Screening: Prior to starting therapy, perform a complete blood count (CBC), serum biochemistry (focusing on liver enzymes and renal function), and a fecal flotation to rule out pre-existing parasitic infections.
  2. Initial Follow-Up (Month 1): For dogs taking Zenrelia, a CBC should be performed 30 days after initiating therapy to monitor for the early development of neutropenia or leukopenia.
  3. Routine Monitoring (Every 6 to 12 Months): Perform a physical exam, check for skin infections (particularly Demodex or bacterial pyoderma), and run a CBC and chemistry panel.
  4. Clinical Intervention: If liver enzymes (ALT/ALP) exceed three times the upper reference limit, or if total white blood cell counts drop below normal reference intervals, the medication should be discontinued, and a washout period initiated before transition to non-JAK therapies.

Frequently Asked Questions

Can I vaccinate my dog while they are taking Apoquel, Zenrelia, or Numelvi?

  • Apoquel: Yes. It has been safely co-administered with inactivated vaccines (like Rabies or Leptospirosis) and maintenance modified-live vaccines. However, you should avoid vaccinating during the first 14 days of twice-daily loading.
  • Zenrelia: No. The label requires discontinuing Zenrelia for 28 days to 3 months before vaccinating, and withholding it for 28 days after vaccination, to ensure the dog develops a proper immune response.
  • Numelvi: Precautions apply. Because atinvicitinib is an immunomodulatory drug, veterinarians should review the patient's individual risk factors before co-administering vaccines.

Does Numelvi have a twice-daily loading phase like Apoquel?

No. Unlike Apoquel, which requires twice-daily dosing for the first 14 days, Numelvi is dosed once daily from the first day of treatment.

Which of the three JAK inhibitors is the most cost-effective?

Generally, Zenrelia is priced lower than Apoquel. Numelvi, as a newly approved brand-name drug, is expected to carry premium pricing, though manufacturer rebates and clinic-loyalty programs may offset costs. Exact pricing varies by veterinary clinic and pharmacy.

What should I do if my dog develops a skin infection while on a JAK inhibitor?

If your dog develops a bacterial skin infection (pyoderma), yeast infection, or demodicosis (mange), consult your veterinarian immediately. The JAK inhibitor may need to be temporarily discontinued while the infection is treated with appropriate antibiotics, antifungals, or antiparasitics, as the drug's immunosuppressive effects can hinder recovery.

Can cats take Numelvi, Apoquel, or Zenrelia?

No. These medications are FDA-approved strictly for dogs. Because feline metabolism and immunological pathways differ significantly, administering canine JAK inhibitors to cats can cause severe toxicity, including bone marrow suppression and fatal infections. There are currently no FDA-approved oral JAK inhibitors for felines.

Sources

Topics
DermatologyDrug Safety & Toxicology
Related Articles